tirzepatide studies 2025 Impact of 1-Year Use on Glycemic and Metabolic Profile in Overweight to Obese People with Type 1 Diabetes: A Systematic Review and Meta-Analysis Read now: The SURPASS-EARLY trial

severe cases may lead to seizures or unconsciousness

Among adults who have ever used GLP-1 drugs, the 15% who say they have not been diagnosed with diabetes, heart disease or as overweight or obese may nonetheless have taken these drugs for treatment of other chronic conditions that these drugs are approved for, such as certain types of liver disease or sleep apnea

Starting with a microdose or slower escalation schedulesuch as PlexusDx's Microdose GLP-1 Protocol at $129/momay also allow a gentler adjustment window

The combined 8 mg group was tracking approximately 20-22% body weight reduction by week 30-36 in the phase 2 trial